Evidence map›Paper›PMID 26439085›Full record

ReviewNature reviews. Microbiology2015

Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus.

Ilhem Messaoudi, Gaya K Amarasinghe, Christopher F Basler

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed
16.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

155 citing papers in PubMed, 252 citations in OpenAlex.

  1. Ebola virus exploits host lncRNAbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. 25 Years of Ebola Virus VP35 Research.Journal of molecular biology · 2025
    Review
  10. Article
  11. Ebola virus VP35 NNLNS motif modulates viral RNA synthesis and MIB2-mediated signaling.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Refining early detection of Marburg Virus Disease (MVD) in Rwanda: Leveraging predictive symptom clusters to enhance case definitions.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
    Article
  17. The Role of Glycans in Human Immunity-A Sweet Code.Molecules (Basel, Switzerland) · 2025
    Review
  18. Article
  19. Marburg Virus Disease: A Narrative Review.Health science reports · 2025
    Article
  20. Article

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Ilhem MessaoudiSchool of Medicine, University of California Riverside, Riverside, California 92521, USA.
Gaya K AmarasingheThe Division of Biology &Biomedical Sciences, Washington University in St. Louis, St. Louis, Missouri 63110, USA.
Christopher F BaslerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
Icahn School of Medicine at Mount Sinai · USUniversity of California, Riverside · USWashington University in St. Louis · US

Funding

Virology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI Gaya K. Amarasinghe · 2016 to 2026
$30.2M
Tissue and Cell Processing CoreU19AI070489 · NIAID · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2006 to 2016
$17.9M
Therapeutics Targeting Filoviral interferon-antagonist and replication functionsU19AI109664 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$15.8M
Molecular mechanisms of immune dysregulation by filoviral interferon U19AI109945 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$9.5M
Ebola VP35 Interferon-Antagonist: Mechanism and SignifR01AI059536 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BASLER, CHRISTOPHER F · 2005 to 2015
$4.2M
Structural studies of Ebola VP35 mediated immune evasion mechanismsR01AI081914 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K. · 2009 to 2013
$2.0M
NIAID NIH HHS P01 AI120943NIAID NIH HHS R01 AI059536NIAID NIH HHS R01 AI081914NIAID NIH HHS U19 AI070489NIAID NIH HHS U19 AI109664NIAID NIH HHS U19 AI109945
6 · The paper itself

Abstract

Ebola viruses and Marburg viruses, members of the filovirus family, are zoonotic pathogens that cause severe disease in people, as highlighted by the latest Ebola virus epidemic in West Africa. Filovirus disease is characterized by uncontrolled virus replication and the activation of host responses that contribute to pathogenesis. Underlying these phenomena is the potent suppression of host innate antiviral responses, particularly the type I interferon response, by viral proteins, which allows high levels of viral replication. In this Review, we describe the mechanisms used by filoviruses to block host innate immunity and discuss the links between immune evasion and filovirus pathogenesis.

Indexed as

Immune EvasionActive Transport, Cell NucleusAnimalsHemorrhagic Fever, EbolaImmunity, InnateInterferonsIntracellular Signaling Peptides and ProteinsKelch-Like ECH-Associated Protein 1Marburg Virus DiseaseSignal TransductionSTAT1 Transcription FactorViral ProteinsViral Regulatory and Accessory ProteinsInterferonsIntracellular Signaling Peptides and ProteinsKEAP1 protein, humanKelch-Like ECH-Associated Protein 1STAT1 Transcription FactorViral ProteinsViral Regulatory and Accessory ProteinsVP24 protein, Ebola virusVP35 protein, filovirus

Identifiers

PMID26439085
PMCPMC5201123
OpenAlexW2238727653

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.